Obesity has become a global health problem and therefore understanding of the mechanisms regulating hunger and satiety is of utmost importance for the development of new treatment strategies. The Y4 receptor, encoded by the NPY4R gene, and its ligand pancreatic polypeptide (PP) have been reported to mediate a satiety signal. Multiple genetic studies have reported an association between NPY4R copy number and body weight. The gene also displays several SNP variants, many of which lead to amino acid differences, making it interesting to study. We have investigated the functional properties of 12 naturally occurring amino acid sequence variants of the Y4 and interpret the results in relation to sequence conservation and our structural model of the human Y4 receptor protein. Met variant has an amino acid replacement located in the TM3 helix, one helix turn above the highly conserved ERH motif. This position has influence on the network of residues involved in receptor activation and subsequent inactivation. Sequence conservation and the structural model are consistent with these results. The remaining seven positions had no significant effect on the receptor's functional response compared to wild-type Y4. These positions display more variation during evolution. Understanding of the interactions between the Y4 receptor and its native PP agonist and the effects of amino acid variation on its functional response will hopefully lead to future therapeutic possibilities.
Introduction
Obesity is a highly heritable disease [1] that has become one of the major health problems across the globe during the past few decades [2] . It is a complex polygenic and multifactorial disease which makes it difficult to study specific genetic factors influencing body weight.
Multiple single nucleotide polymorphisms (SNPs) and gene copy number variation (CNV) regions are associated with obesity [3] [4] [5] [6] [7] [8] [9] . One such CNV region is located at 10q11.22 [9] [10] [11] [12] and it encompasses the three genes NPY4R, GPRIN2 and SYT15. Out of the three, NPY4R is the most likely candidate to play a role in energy metabolism and obesity development.
The NPY4R gene encodes the Y4 receptor which belongs to the neuropeptide Y (NPY) family of rhodopsin-like (class A) G protein-coupled receptors. Like all GPCRs, they are comprised by seven transmembrane helices (TM) connected with intracellular (ICL) and extracellular loops (ECL). Humans have four functional NPY-family receptor subtypes: Y1, Y2, Y4 and Y5 [13] and a pseudogenised Y6 receptor.
In mammals, the NPY family of peptides consists of three members: NPY, peptide YY (PYY) and pancreatic polypeptide (PP). All three peptides are 36 amino acids long, have an amidated carboxyterminal tyrosine and share considerable sequence identity [14] . The NPY family peptides regulate energy metabolism, hunger and satiety [15] , lipid metabolism and insulin secretion [16, 17] , as well as many other physiological parameters. NPY stimulates appetite [18] through the Y1 and Y5 receptors [19] . In contrast, PYY and PP inhibit appetite [20] [21] [22] [23] [24] , PYY acting primarily on Y2 [20] and PP on Y4 [22] .
A structural model for the human Y4 receptor has been proposed based on crystal structures for other class A receptors followed by mutagenesis and measurements of functional response to PP stimulation [25] . Several residues in the outer parts of the transmembrane regions were identified to be important for receptor activation by PP. The Y4 receptor like the other NPYR family subtypes can couple via Gi and Go as well as Gq [26] .
Among the NPY family receptors, Y4 is the fastest evolving functional member [27] . NPY4R displays multiple SNPs and was duplicated in the common ancestor of Denisovans, Neanderthals and the modern human (Shebanits et al., submitted). We have recently reported that the CNV ranges from 2 to 8 copies in one study sample [28] and from 3 to 11 in a different study sample (Shebanits et al., in preparation) . The extensive CNV and the substantial SNP variation make the NPY4R gene a challenge to study, but due to its role in appetite inhibition the Y4 receptor is an attractive target for anti-obesity drug development. Understanding of the interactions between Y4 and PP, the consequences of the genetic variation, both CNV and SNP, will hopefully facilitate studies of therapeutic possibilities.
In our previous investigations of the copy number and sequence variation of the NPY4R gene we identified 12 SNP variants resulting in amino acid changes. We report here studies of the functional response of all of these naturally occuring sequence variants of the Y4 receptor protein. We interpret the results in the light of extensive evolutionary sequence comparisons of Y4 across vertebrates as well as with other NPY-family receptor subtypes and more distantly related peptide receptors. Furthermore, we have generated a structural model of the Y4 receptor that provides the structural basis for interpretation of the functional results.
Methods

Study Samples
We have screened the coding part of the NPY4R for SNPs in 24 individuals from 1000 Genomes Project (NA10847, NA10851, NA12155, NA12717, NA12878, NA18504,  NA18510, NA18517, NA18519, NA18524, NA18529, NA18536, NA18542, NA18603, A C C E P T E D M A N U S C R I P T 4 NA18627, NA18745, NA18760, NA18795, NA18940, NA18948, NA18949, NA18959, NA18961, NA19238) [29] and used the data from the Northern Sweden Population Health Study (NSPHS) in order to find non-sense and miss-sense mutations. We have studied 12 mutated versions of Y4 receptor.
Mutant analysis of 24 samples from 1000 Genomes Project
A number of PCR primes that cover the whole gene in a step-wise fashion was developed to analyse the SNPs in the coding part of the NPY4R (Supplementary Table 1 ).
Numbering and nomenclature used for receptor residues
Mutants are named using three-letter abbreviations for the amino acid residue, followed by a sequence correlative number and the introduced amino acid. Superscripts following receptor residue numbers denote N-terminus (NT), extracellular loop 2 (ECL2) and GPCR numbering according to Ballesteros and Weinstein. The most conserved residue in a TM is designated x.50, where x is the TM number. All other residues on the same TM region are numbered relative to this reference residue.
Site-directed mutagenesis
A pcDNA3. 
Functional Assay
The inositol phosphate (IP) assay was performed by cotransfection of each receptor plasmid with a chimeric G-protein plasmid. The chimeric Gq-protein (curtesy of E. Kostenis) has last four amino acids replaced by the corresponding amino acids from Gi and can change a Gi signal transduction pathway to the Gq pathway, leading to IP generation [30] . Human embryonic kidney (HEK) 293 cells at 90-95% confluence were cotransfected with the chimeric Gi4 and either a WT hY4 plasmid or the mutant hY4 plasmids, using Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific) and Opti-Mem cell culture medium (Thermo Fisher Scientific) according to the manufacturer's protocol. Myo2-3 Hinositol (PerkinElmer) at 3 Ci/mL was added the next day. On the following day, the cells were detached with PBS/EDTA mixture (0.2g/L) and resuspended in the IP assay buffer (10 mM LiCl, 20 mM Hepes, 137 mM NaCl, 5m M KCl, 0.44 mM KH 2 PO 4 , 4.2 mM NaHCO 3 , 1.2 mM MgCl 2 , 1 mM CaCl 2 , and 10 mM glucose). The cells were preincubated for 10 min and then stimulated with serial dilution of hPP for 30 min at 37 °C. An equal volume of ice-cold 0.8 M perchloric acid was added and incubated on ice for 30 min to lyse the cells. The reaction was terminated by using a neutralising buffer (KOH/KHCO 3 ). Ion exchange chromatography on AG 1-X8 resin (Bio-Rad) was used to isolate the generated  3 Hinositol phosphates. The resin was washed with 5 nM Na 2 B 2 and 60 mM NH 4 -formate, and the  3 Hinositol phosphates were eluted with 1 M NH 4 -formate and 0.1 M formic acid (method
adapted from Johansson et al. 2007 [31] ). Following elution, the samples were mixed with OptiPhase HiSafe (PerklinElmer) and the 3 H radioactivity was measured with a liquid scintillation counter (PerklinElmer). Each sample was run in duplicates for each concentration and each assay was performed in triplicates. WT hY4 was used as a reference in each run.
Detection of receptor expression
Coverslips were coated with 0.1 mg/mL poly-D-lysine and were seeded with HEK 293 cells transiently expressing WT hY4 or mutant receptors. Cells, transfected without a plasmid, were used as a negative control. Cells were cultured for 48 h at 37 °C in 5% CO 2 . The coverslips were washed twice with PBS and the cells were fixed with 70% ethanol for 10 minutes. The coverslips were mounted upside down on glass slides using DAPI-containing mounting medium. Acquired fluorescence was detected with an inverted confocal microscope (Zeiss LSM 510 Meta, Carl Zeiss Inc., Thornwood, NY) and a 63 oil immersion objective (NA=1.4) and visualized via the accompanying LSM software (Carl Zeiss Inc.). The colours during microscopy were distinctly green (hY4-eGFP) or blue (cell nuclei). However, due to a technical problem with the camera filters during photography, some green fluorescence leaked into the blue channel in the photographs leading to cyan instead of green (Supplementary Figure 1) . This artifact was absent in negative control (cells that were not transfected with plasmid containing eGFP) (Supplementary Figure 1) .
Data analysis
To calculate the EC50 values of PP for Y4 and mutants, the functional assay data was analyzed with the GraphPad Prism 5.0 software using non-linear regression curve fitting function. For each receptor, the assays were performed at least three times. The results were presented as geometric mean with 95% confidence interval ( Table 1 ). The statistical analyses of pEC50 were performed using one-way ANOVA with Dunnett post hoc tests (Figure 3 ). P<0.01 is used to define statistically significant difference.
Homology modelling
A model of the Y4 receptor was generated with the GPCR-ModSim web server (http://open.gpcr-modsim.org) [32] following the protocol for homology modelling reported in [33] . Briefly, after obtaining a multiple sequence alignment of the Y4 sequence (from position 22 to position 340) against the curated crystallized GPCRs in fully active conformation available in the server, three templates were chosen to model the Y4 receptor in its active state: the human M2 muscarinic acetylcholine receptor (PDB code 4mqs), metarhodopsin II (PDB code 3pqr) and the beta2 adrenergic receptor (PDB code 3sn6). The server provides a pairwise sequence identity for each region of the GPCR in order to select the best template(s) for each segment. The alignment of the sequences was manually modified to account for distorsions of the transmembrane helices and 50 models were generated, following the protocol of Modeller [34] (embedded in the webserver), and complying with the set of spatial restraints and the sequence alignment previously created. The models were ranked based on the value of scoring function and their stereochemical quality was evaluated with Molprobity [35] : the best model was chosen for the representation of the Y4 receptor. Figure 1 . 
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Analysis of receptor variants
Functional assay of PP for WT Y4 and Y4 mutants
All of the receptor variants were generated by mutagenesis of a wild-type Y4 receptor construct in the pcDNA3.1-C-eGFP vector and functionally expressed after transfection of HEK 293 cells. We used a functional assay measuring inositol phosphate turnover in order to study the in vivo signaling of the mutated receptors in comparison with the WT Y4 receptor in response to the natural agonist human PP. Y4 is naturally coupled to the Gi protein, but in order to study the production of the inositol phosphates, the chimeric Gq-protein with the last four C-terminal residues from Gi was co-transfected with the Y4 plasmid. All Figure 2 , Figure 3 ). Both of these displayed a rather modest difference to the wild-type, but nevertheless significant with p<0.001 and p<0.01, respectively.
A C C E P T E D M A N U S C R I P T
The response was completely absent in three of the variants, namely Cys201 ECL2 Tyr, Val271 6 .41 Leu and Asn318 7.49 Asp. All three were expressed on the cell surface as shown by fluorescence of the eGFP tag, although Val271 6.41 Leu had considerable fluorescence in intracellular vesicles and Asn318 7.49 Asp had low albeit clear cell surface expression (not shown).
The remaining seven variants showed no difference to the WT receptor in their functional response (Figure 3) . 
Homology modelling
A model of the human Y4 receptor was generated as described in the methods section. The structural information obtained with homology modelling of Y4 helps with the qualitative interpretation of the mutagenesis data as described below.
The loss of receptor response in the case of Cys201Tyr is explained by the disruption of the disulphide bridge with Cys114 faces the membrane and this position is deep in the bilayer, thus the mutation into Thr does not have a detrimental effect on PP potency. The sidechain of Ala99 2.62 , instead, faces TM1 and it is found in a very hydrophobic environment, with the exception of Tyr48 1.39 , whose hydroxyl group points away from Ala99 2.62 . Its mutation into Ser is not easily accepted in such surroundings, although no sterical clash arises. The Thr126 3.37 Met variant is a big change in the physical characteristics of the sidechain, but the potency appears unaltered, probably due to the absence of polar interactions involving the threonine sidechain and the possible accommodation of the bulky sidechain of methionine between TM3 and TM5. According to our model, Arg239 5.63 and Arg240 5.64 are positioned in the lower part of TM6 with their sidechains exposed to the solvent. Moreover, they are surrounded by other arginines. The change of Arg239 5.63 into Trp or Gln and the change of Arg240 5.64 to Cys do not affect the receptor response to its agonist PP most probably because they do not cause major changes in the part of the receptor involved in the ligand or G protein binding.
The final variant Val276 6.46 Met involves a valine sidechain that is completely surrounded by the lipid membrane why its change into methionine would not be expected to have any effect on the potency.
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Discussion
Due to the complex genetics of the NPY4R gene, displaying both extensive CNV and SNP variation, it is not possible to discuss the amino acid variants in terms of allelic products. Rather, we cautiously call them receptor variants, as they may arise either from distinct copies of the NPY4R gene on the same chromosome or from alleles for either of the duplicates.
We identified twelve naturally occurring Y4 variants in the two study samples that we have analysed. Three of these variants were found in both of the cohorts: Val271 6.41 Leu [36] , Arg240 5.64 Cys and Val276 6.46 Met [37] . These are the only ones that have been investigated pharmacologically before, to our knowledge. The remaining nine variants were found either in one or the other of the two cohorts. One of these, Ala81 2.44 Thr , was analysed in one of the previous studies, but only in silico, where it was predicted to have no effect [36] .
Three of the variants produced no functional response at all, namely Cys201 ECL2 Tyr Val271 6.41 Leu and Asn318 7.49 Asp. Cells transfected with Cys201 ECL2 Tyr exhibited membrane expression but had a high number of vesicles containing the receptor (Supplementary Figure  1) . The loss of response for Cys201Tyr was expected because this cysteine forms a disulphide bond with Cys114 in ECL1, holding together this region with ECL2, in a large number of class A GPCRs including all of the NPYR subtypes and species. Presumably this disulphide is required for the NPY receptors to form a functional binding site for the native peptide agonists.
Cells transfected with Val271 6.41 Leu displayed membrane expression and, as well as Cys201 ECL2 Tyr, had a high number of vesicles containing the receptor (Supplementary Figure  1 ). Our structural model shows that this side chain is surrounded by three Leu side chains why a Leu also at position 271 may make this space too crowded, resulting in a distorted receptor structure. This Val at this position is highly conserved in all NPY-family receptors except two Y4 sequences that have Ile (a shark and a pufferfish) and most of the Y5 sequences which likewise have an Ile. Thus, only Val and Ile seem to be generally acceptable at this position in the NPYR family. The related receptors for NPFF, PRLP and QRFP have either Val or Ala at this position (see Fig. 5 [38] ).
The complete loss of response for the change Asn318 7.49 Asp was expected because it affects a functionally crucial residue with very high conservation not only across species for Y4 and across NPY-family receptor subtype, but also in many other class A GPCRs. Asn318 7.49 interacts with Asp105 2.50 to regulate receptor activation-inactivation (see [39] ). A change of Asn318 7.49 to Asp may interfere with the nearby Asp87 2.50 according to our structural model. Two receptor variants displayed significantly reduced potency, requiring more than 4-fold higher PP concentration at EC50. Regarding the Cys34 NT Ser variant, Cys34 forms a disulphide bond with Cys298 at the outer end of ECL3. This cysteine pair is found in all Y1-subfamily receptors, i.e., Y1, Y4, Y6 and Y8 (lost in mammals). However, it does not exist in Y2, Y5, or Y7 suggesting that it is not absolutely essential for NPYR function. Therefore, it is not unexpected that the Cys34Ser variant is expressed on the cell surface (Supplementary Figure 1) . The Val135 3.46 Met variant involves an amino acid replacement rather deep in the TM3 helix, just one helix turn above the highly conserved ERH motif. This position may have some interaction with the network of residues involved in receptor activation and subsequent inactivation. Indeed, it is highly conserved across NPY receptor subtypes, having and Ile in all subtypes including Y4 in most species except mammals, all of which have a Val. Also the closest relatives of the NPYR family have and Ile, namely the receptors for NPFF, PRLP and QRFP (see Fig. 5 in [38] ). The structural model shows that a Met at this position will have A C C E P T E D M A N U S C R I P T (Figure 3 ). All of these display more variability among species and NPY receptor subtypes and are likely to represent more or less neutral variants. Detailed analyses of the structural model Fig. 4 shows that these positions seem able to accommodate that variant amino acid side chains without obvious disturbance of either receptor structure, ligand binding or G protein interaction.
Thus, in conclusion, our analyses of the functional responses of twelve naturally occurring Y4 receptor variants are in good agreement with the degree of variation at each of these positions across species and NPYR subtypes, and also other class A GPCRs. The functional consequences of the genetic variation of NPY4R is likely to be a combination of gene copy number variation, amino acid changes and differences in regulatory regions of the genes. Hence, it is not immediately obvious how much each variant gene may contribute to the phenotype of the carrier of that variant, neither the three variants that have lost functional response nor the two that have a reduced functional response. If these variants would occur in individuals with only two or three rather than several more copies of the NPY4R gene, it is of course more likely that they will cause a reduction in the physiological response to PP.
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18 Highlights  Naturally occurring mutations alter response of Y4 receptor to its ligand  Evolutionary conserved residues are important for receptor structure and functions  Modelling helps to understand the role of specific residues in receptor functions
